BE904547A - Nouveaux medicaments a usage topique. - Google Patents

Nouveaux medicaments a usage topique.

Info

Publication number
BE904547A
BE904547A BE1/011467A BE1011467A BE904547A BE 904547 A BE904547 A BE 904547A BE 1/011467 A BE1/011467 A BE 1/011467A BE 1011467 A BE1011467 A BE 1011467A BE 904547 A BE904547 A BE 904547A
Authority
BE
Belgium
Prior art keywords
topical use
new medicines
salt
pharmacologically active
hyaluronic acid
Prior art date
Application number
BE1/011467A
Other languages
English (en)
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE904547(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT48980/85A external-priority patent/IT1184675B/it
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of BE904547A publication Critical patent/BE904547A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Préparations pharmaceutiques pour l'administration topique contenant une substance pharmacologiquement active en meme temps que de l'acide hyaluronique ou une des ses fractions moléculaires. L'acide hyaluronique peut exister sous la forme d'acide libre ou sous la forme de sel avec un métal alcalin ou alcalino-terreux, le magnésium, l'aluminiué ou l'ammonium ou sous la forme d'un sel avec une ou plusieurs substances pharmacologiquement actives.
BE1/011467A 1985-04-05 1986-04-03 Nouveaux medicaments a usage topique. BE904547A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (it) 1985-04-05 1985-04-05 Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CN85102921A CN85102921B (zh) 1985-04-05 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法
IT48980/85A IT1184675B (it) 1985-12-23 1985-12-23 Procedimento per la preparazione di sali dell'acido ialuronico

Publications (1)

Publication Number Publication Date
BE904547A true BE904547A (fr) 1986-10-03

Family

ID=36694284

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/011467A BE904547A (fr) 1985-04-05 1986-04-03 Nouveaux medicaments a usage topique.

Country Status (27)

Country Link
US (1) US4736024A (fr)
EP (2) EP0555898A3 (fr)
JP (2) JP2585216B2 (fr)
KR (1) KR910006810B1 (fr)
CN (1) CN85102921B (fr)
AR (1) AR245369A1 (fr)
AT (1) ATE98495T1 (fr)
AU (1) AU592077B2 (fr)
BE (1) BE904547A (fr)
CA (2) CA1340825C (fr)
CH (1) CH672886A5 (fr)
DE (1) DE3689384T3 (fr)
DK (1) DK149886A (fr)
ES (1) ES8800055A1 (fr)
FI (1) FI83966C (fr)
FR (1) FR2579895B1 (fr)
HU (1) HU204202B (fr)
IE (1) IE64440B1 (fr)
IL (1) IL78263A0 (fr)
IN (1) IN165867B (fr)
IT (1) IT1229075B (fr)
LU (1) LU86386A1 (fr)
NO (1) NO174277C (fr)
NZ (1) NZ215676A (fr)
PH (1) PH29979A (fr)
PT (1) PT82342B (fr)
ZA (1) ZA862463B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3806B (en) 1989-02-24 1996-03-25 Richter Gedeon Vegyeszet Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution
BG64458B1 (bg) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. Използване на цинков хиалуронат срещу пептична язва
EP2289522A1 (fr) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Utilisation d'acide hyaluronique pour le traitement d'ulcers gastro-duodenaux
EP2292243A1 (fr) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique pour traiter et empêcher les maladies intestinales inflammatoires
EP2543357A1 (fr) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition pour une utilisation dans le traitement et la prévention d'une maladie liée à l'inflammation
EP2545925A1 (fr) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprenant de l'acide hyaluronique pour le traitement et la prévention de maladies liées aux muqueuses
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1186772B (it) * 1985-10-10 1987-12-16 Crinos Industria Farmaco Composto ad attivita' pilostimolante
AU600483B2 (en) * 1986-03-14 1990-08-16 Bio-Technology General Corporation Heavy metal salts of hyaluronic acid
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
CA1327354C (fr) * 1987-03-19 1994-03-01 David Cullis-Hill Composes et compositions anti-inflamatoires
ES2024641B3 (es) * 1987-05-20 1992-03-01 Kk Ueno Seiyaku Oyo Kenkyujo Preservativo.
IL86933A (en) * 1987-07-01 1993-07-08 Genentech Inc Method and therapeutic compositions for the prevention of fibrin deposition for adhesions
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
JPH01213227A (ja) * 1988-02-23 1989-08-28 Tadashi Koyake 軟膏剤及び液剤
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
JPH0232013A (ja) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
JPH02200624A (ja) * 1989-01-30 1990-08-08 Nippon Kayaku Co Ltd 歯科用包帯剤
US6458774B1 (en) * 1989-02-24 2002-10-01 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing hyaluronic acid associates and a process for preparing same
US5472950A (en) * 1989-02-24 1995-12-05 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing cobalt hyaluronic acid complex
CA1340994C (fr) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
NL8903155A (nl) * 1989-12-23 1991-07-16 Stamicarbon Harssamenstelling op basis van een polyesterhars, een aminohars en een epoxyhars.
WO1991011992A1 (fr) * 1990-02-13 1991-08-22 Zerega Gere S Di Medicaments induits au niveau peritoneal
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061566C (fr) * 1992-02-20 2002-07-09 Rudolf E. Falk Traitement des maladies par l'acide hyaluronique et des ains
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061703C (fr) * 1992-02-20 2002-07-02 Rudolf E. Falk Compositions renfermant de l'acide hyaluronique
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5492936A (en) * 1990-11-30 1996-02-20 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1994007505A1 (fr) * 1991-07-03 1994-04-14 Norpharmco Inc. Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle
AU3658793A (en) * 1992-02-10 1993-09-03 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
CA2061567C (fr) * 1992-02-20 1998-02-03 Rudolf E. Falk Utilisation de l'acide hyaluronique pour reparer les dommages de reperfusion de l'ischemie
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
CA2130762C (fr) * 1994-08-24 1999-07-06 Eva Anne Turley Traitement des maladies et des troubles associes a l'infiltration par des macrophages
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
EP0613907A3 (fr) * 1993-03-04 1995-05-24 Genzyme Ltd Réduction contrÔlée du poids moléculaire de polymères.
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
CA2154103C (fr) * 1995-07-18 1998-02-24 Samuel Simon Asculai Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
IT1287227B1 (it) * 1996-04-04 1998-08-04 Fidia Spa In Amministrazione S Acido ialuronico quale componente del liquido di conservazione della cornea
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6451326B2 (en) 1996-05-02 2002-09-17 Burt D. Ensley Cosmetic compositions
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
US5843186A (en) * 1996-12-20 1998-12-01 Implemed, Inc. Intraocular lens with antimicrobial activity
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
DK0971961T3 (da) * 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
DE69833665T2 (de) 1997-08-08 2006-11-09 Duke University Zusammensetzungen zur vereinfachung von chirurgischen verfahren
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
DK172900B1 (da) * 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
US8003782B1 (en) * 1999-02-01 2011-08-23 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2001275085A1 (en) 2000-06-01 2001-12-11 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US7879824B2 (en) * 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
WO2002043785A2 (fr) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Procedes permettant de reduire ou prevenir le rejet de greffe dans l'oeil et implants intraoculaires utilises a cet effet
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
NZ532278A (en) * 2001-09-19 2006-02-24 Altana Pharma Ag Combination of a PDE inhibitor and an NSAID
ITMI20021666A1 (it) * 2002-07-26 2004-01-26 Jasper Ltd Liability Co Derivati dell'acido ialuronico
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2005016386A1 (fr) * 2003-08-19 2005-02-24 Meditech Research Limited Protocoles therapeutiques ameliores
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
CA2553381C (fr) 2004-01-20 2011-03-22 Allergan, Inc. Compositions pour traitement local de l'oeil, comprenant de preference de l'acetonide de triamcinolone et de l'acide hyaluronique
FR2865651B1 (fr) 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
BRPI0515427A (pt) * 2004-09-21 2008-07-22 Advanced Medical Optics Inc solução viscoelástica ou formulação em gel, e métodos de tratamento de um local do corpo com estas
EP1721602A1 (fr) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Système d'administration orale de médicaments à libération contrôlée
FR2888752B1 (fr) * 2005-07-22 2007-10-05 Fabre Pierre Dermo Cosmetique Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
CN101287474B (zh) * 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
MY149606A (en) * 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007038252A2 (fr) * 2005-09-22 2007-04-05 Key Douglas J Methodes et compositions de traitement des plis de la peau et les rides et ameliorant la qualite de la peau
JP4555232B2 (ja) * 2006-01-25 2010-09-29 Ｈｏｙａ株式会社 組織の蛍光染色方法
US8668676B2 (en) 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
JP2009541372A (ja) * 2006-06-28 2009-11-26 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ 複数のヒアルロン酸画分を含む化粧用と医療用の組成物
WO2008003321A2 (fr) * 2006-07-07 2008-01-10 Novozymes Biopolymer A/S Compositions avec plusieurs fractions d'acide hyaluronique destinées à un usage cosmétique
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
ES2621876T3 (es) 2006-09-13 2017-07-05 Enhance Skin Products Inc. Composición cosmética para el tratamiento de la piel y procedimientos de la misma
US8466128B2 (en) 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
EP2818184B1 (fr) 2007-11-16 2018-10-31 Allergan, Inc. Compositions Et Procédés De Traitement Du Purpura
CA2724607A1 (fr) * 2008-05-30 2009-12-31 Fairfield Clinical Trials, Llc Procede et composition pour une inflammation et une decoloration de la peau
WO2010003797A1 (fr) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Acide hyaluronique pour la cicatrisation cornéenne
US8624077B2 (en) 2008-10-02 2014-01-07 L.R.R.&D. Ltd. Interface layer wound dressing
CN101385874B (zh) * 2008-10-23 2012-11-28 武汉大学 一种含有高分子透明质酸的生物滑液的制备方法
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
JP2012526819A (ja) * 2009-05-11 2012-11-01 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド 脂質−ポリマー複合体、その調製、及びその使用
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
IT1407283B1 (it) * 2010-12-06 2014-04-04 Paoli Ambrosi De Nuovo composto di carnosina
CZ303548B6 (cs) 2011-01-05 2012-11-28 Contipro Pharma A.S. Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje
CZ22394U1 (cs) 2011-03-11 2011-06-20 Contipro C, A.S. Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem
ITMI20111747A1 (it) 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
KR101412776B1 (ko) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
CN103319627A (zh) * 2013-07-10 2013-09-25 南宁中诺生物工程有限责任公司 一种对透明质酸钠进行分子量分级的方法
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
JP2017505805A (ja) * 2014-02-11 2017-02-23 オラシス ファーマシューティカルズ リミティド 老眼矯正に使用される眼科用薬理組成物及びその投与
EP2910255A1 (fr) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Procédés de production de biopolymères à masse moléculaire moyenne définie
US9603867B2 (en) * 2015-03-03 2017-03-28 Yung Shin Pharm. Ind. Co., Ltd. Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
US10973858B2 (en) * 2016-02-12 2021-04-13 Laimu Corporation Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same
WO2018033792A2 (fr) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Compositions pharmaceutiques ophtalmiques et utilisations associées
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液
CN107802597B (zh) * 2017-12-08 2020-07-31 北京诺康达医药科技股份有限公司 一种玻璃酸钠组合物及其制备方法和应用
PT3740191T (pt) * 2018-01-18 2021-07-09 Faes Farma Sa Composições oftálmicas compreendendo bilastina, uma beta-ciclodextrina e pelo menos um agente gelificante
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
IT201800010415A1 (it) * 2018-11-19 2020-05-19 Innate S R L Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
WO2023091439A1 (fr) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Dérivés d'acéclidine, leurs compositions et leurs procédés d'utilisation
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
DE1047380B (de) * 1954-08-18 1958-12-24 American Home Prod Verfahren zur Herstellung einer hyaluronidasefreien, teilweise depolymerisierte Hyaluronsaeure enthaltenden waessrigen Traegerloesung fuer Arzneimittel
GB818336A (en) * 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
FR1425265A (fr) * 1962-05-14 1966-01-24 Parke Davis & Co Procédé de préparation d'un nouveau polysaccharide et de ses sels
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US3936081A (en) * 1974-02-27 1976-02-03 R & G Sloane Manufacturing Co., Inc. Pipe joint and method of making same
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
HU172937B (hu) * 1975-12-18 1979-01-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh khondroitin-sernoj kisloty s mestno anestezirujuhhim ehffektom
SE7901565L (sv) * 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
JPS55153711A (en) * 1979-05-19 1980-11-29 Pola Chem Ind Inc Cosmetic lotion
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4359458A (en) * 1981-09-28 1982-11-16 American Cyanamid Company O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
JPS591405A (ja) * 1982-06-28 1984-01-06 Shiseido Co Ltd 乳化組成物
JPS597106A (ja) * 1982-07-06 1984-01-14 Shiseido Co Ltd 乳化組成物
JPS5920212A (ja) * 1982-07-27 1984-02-01 Shiseido Co Ltd 乳化組成物
JPS5939338A (ja) * 1982-08-30 1984-03-03 Shiseido Co Ltd 乳化組成物
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
EP0138752B1 (fr) * 1983-08-12 1986-11-12 Ciba-Geigy Ag Pigments monocliniques au chromate de plomb
DE3334595A1 (de) * 1983-09-24 1985-04-18 B. Braun Melsungen Ag, 3508 Melsungen Wirkstoffdepot
FR2553099B1 (fr) * 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS61180723A (ja) * 1985-02-06 1986-08-13 Sanwa Kagaku Kenkyusho:Kk 易吸収性カリジノゲナ−ゼ製剤用組成物
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
WO1991011992A1 (fr) * 1990-02-13 1991-08-22 Zerega Gere S Di Medicaments induits au niveau peritoneal

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3806B (en) 1989-02-24 1996-03-25 Richter Gedeon Vegyeszet Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution
BG64458B1 (bg) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. Използване на цинков хиалуронат срещу пептична язва
EP2289522A1 (fr) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Utilisation d'acide hyaluronique pour le traitement d'ulcers gastro-duodenaux
EP2292243A1 (fr) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique pour traiter et empêcher les maladies intestinales inflammatoires
EP3842046A1 (fr) 2009-08-14 2021-06-30 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique permettant de traiter et d'empêcher les maladies intestinales inflammatoires
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
EP2543357A1 (fr) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition pour une utilisation dans le traitement et la prévention d'une maladie liée à l'inflammation
EP2545925A1 (fr) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprenant de l'acide hyaluronique pour le traitement et la prévention de maladies liées aux muqueuses
US10709731B2 (en) 2011-07-12 2020-07-14 Aihol Corporation Materials for treating and preventing mucosa related disease

Also Published As

Publication number Publication date
LU86386A1 (fr) 1986-09-02
EP0197718A2 (fr) 1986-10-15
JP2585216B2 (ja) 1997-02-26
DE3689384D1 (de) 1994-01-27
JP2677778B2 (ja) 1997-11-17
NO174277C (no) 1994-04-13
ES8800055A1 (es) 1987-11-16
DK149886D0 (da) 1986-04-02
CN85102921B (zh) 1988-06-08
FI83966C (fi) 1991-09-25
CN85102921A (zh) 1986-10-08
ATE98495T1 (de) 1994-01-15
ZA862463B (en) 1987-12-30
ES553714A0 (es) 1987-11-16
EP0197718B1 (fr) 1993-12-15
HU204202B (en) 1991-12-30
PT82342B (pt) 1988-03-03
FI861395L (fi) 1986-10-06
NO174277B (no) 1994-01-03
KR910006810B1 (ko) 1991-09-02
FR2579895A1 (fr) 1986-10-10
CA1340825C (fr) 1999-11-23
DE3689384T2 (de) 1994-07-07
DK149886A (da) 1986-10-06
NO861331L (no) 1986-10-06
FI861395A0 (fi) 1986-04-01
EP0555898A2 (fr) 1993-08-18
KR860008202A (ko) 1986-11-12
PH29979A (en) 1996-10-29
IT1229075B (it) 1991-07-17
IE860847L (en) 1986-10-05
AR245369A1 (es) 1994-01-31
CH672886A5 (fr) 1990-01-15
EP0197718A3 (en) 1987-09-09
PT82342A (en) 1986-05-01
CA1341418C (fr) 2003-01-21
IT8547924A0 (it) 1985-04-05
FR2579895B1 (fr) 1990-11-23
JPS61236732A (ja) 1986-10-22
HUT40579A (en) 1987-01-28
IL78263A0 (en) 1986-07-31
FI83966B (fi) 1991-06-14
IN165867B (fr) 1990-02-03
AU5566286A (en) 1986-10-16
EP0197718B2 (fr) 2001-07-25
JPH09169667A (ja) 1997-06-30
IE64440B1 (en) 1995-08-09
AU592077B2 (en) 1990-01-04
US4736024A (en) 1988-04-05
EP0555898A3 (fr) 1993-10-20
NZ215676A (en) 1989-08-29
DE3689384T3 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
BE904547A (fr) Nouveaux medicaments a usage topique.
MA21264A1 (fr) Composition permettant d'administrer un medicament sous forme de gellules, d'une poudre ou d'un liquide.
FR2598319B1 (fr) Forme posologique pour delivrer une composition de medicament a un milieu d'utilisation
BE901667A (fr) Composition analgesique et anti-inflammatoire a base de diphenhydramine, leur preparation et leur utilisation.
BE1002159A5 (fr) Adsorbats medicamenteux.
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2442054A1 (fr) Proteines purifiees, notamment interferon, procede de preparation et compositions pharmaceutiques les contenant
CA2246289A1 (fr) Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
DE69319440D1 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
FR2719999B1 (fr) Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
BE873843A (fr) Carbonate basique d'aluminium et de magnesium, sa preparation et compositions pharmaceutiques en contenant
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
BE1002665A4 (fr) Nouvelle forme cristalline de la ciclosporine, sa preparation et les compositions pharmaceutiques la contenant.
FR2378523A1 (fr) Medicament pour le traitement de l'acne
FR2453649A1 (fr) Composition pharmaceutique a action prolongee contenant des acides biliaires utile notamment pour la lyse des calculs
BG104527A (en) Formulations comprising dissolved paroxetine
KR910009267A (ko) 우울증의 치료방법
CA2205664A1 (fr) Derives d'indole et leur utilisation medicinale
IT8722031A0 (it) Formulazioni farmaceutiche e forme di dosaggio per la somministrazione rettale di calcitonina.
MA26698A1 (fr) Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation
FR2391202A1 (fr) Triazines-1,2,4 substituees, actives pharmacologiquement et medicaments contenant ces triazines
BE902055A (fr) Preparations pharmaceutiques.
ES283591Y (es) Una tableta de dosificacion farmaceutica adecuada para administracion oral
FR2515516B1 (fr) Composition pharmaceutique pour le traitement de la lithiase renale infectee contenant de l'acide propionohydroxamique ou ses sels acceptables en pharmacie

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *FIDIA S.P.A.

Effective date: 20060403